FUSION PHARMACEUTICALS
FPI-2265 (225Ac-PSMA-I&T) for Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: FPI-2265
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06402331
- Locations
- πΊπΈ
Hoag Health Center Irvine, Irvine, California, United States
πΊπΈVA Greater Los Angeles Healthcare System, Los Angeles, California, United States
πΊπΈBiogenix Molecular, LLC, Miami, Florida, United States
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
- Conditions
- Advanced Solid TumorNon-small Cell Lung CancerMetastatic Colorectal CarcinomaHead and Neck Squamous Cell CarcinomaPancreatic Ductal Adenocarcinoma
- Interventions
- Drug: FPI-2053Drug: [111In]-FPI-2107Drug: [225Ac]-FPI-2068
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06147037
- Locations
- πΊπΈ
Hoag Hospital, Irvine, California, United States
πΊπΈStanford Hospital and Clinics, Stanford, California, United States
πΊπΈUniversity of Chicago, Chicago, Illinois, United States
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
- Conditions
- Gastric CancerPancreatic Ductal Adenocarcinoma (PDAC)Colorectal CancerSquamous Cell Carcinoma of Head and NeckNeuroendocrine Differentiated (NED) Prostate CancerEwing SarcomaNTSR1 Expressing Solid Tumours
- Interventions
- Drug: [225]-FPI-2059Drug: [111In]-FPI-2058
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05605522
- Locations
- πΊπΈ
Hoag Family Cancer Institute, Newport Beach, California, United States
π¦πΊWestmead Hospital, Sydney, New South Wales, Australia
πΊπΈUniversity of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
- Conditions
- Bladder CarcinomaHead and Neck Squamous Cell CarcinomaSusceptible FGFR3 Genetic AlterationsBreast CancerFGFR3 ReceptorFGFR3 Protein OverexpressionColorectal CancerLiver CancerAdvanced Solid TumorFGFR3
- Interventions
- Drug: [225Ac]-FPI-1966Drug: [111In]-FPI-1967Biological: vofatamab
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05363605
- Locations
- π¦πΊ
St Vincent's Hospital, Melbourne, Australia
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈUniversity of California, San Francisco, San Francisco, California, United States
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Drug: FPI-2265
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT05219500
- Locations
- πΊπΈ
XCancer Omaha/Urology Cancer Center, Omaha, Nebraska, United States
πΊπΈExcel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
- Conditions
- Advanced Solid TumoursEndometrial CancerBreast CancerTriple Negative Breast Cancer (TNBC)Cervical CancerOvarian CancerHER2-negative Breast CancerAdrenocortical CarcinomaUveal MelanomaHead and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Drug: [111In]-FPI-1547 InjectionDrug: [225Ac]-FPI-1434 Injection single-doseDrug: [225Ac]-FPI-1434 Injection multi-doseBiological: FPI-1175 Infusion
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 253
- Registration Number
- NCT03746431
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States